Skin tight: Debt hits derm, quiz Valeant 'core' values in $2B-plus assets sell-off
During a third-quarter earnings conference call in November with investors, when asked about divestitures that could help the company chip away at major debt and focus on the main business, Valeant Pharmaceuticals International Inc. CEO Joe Papa said "core assets for us are the dermatology, the gastrointestinal [GI], the eye-care and the consumer side, but we did receive a number of inbound requests to acquire some of our product assets with very significant numbers that we have to evaluate."
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST